Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 303-310

  Dasta, Joseph F ^a   Pilon, Dominic ^b   Mody, Samir H ^c   Lopatto, Jessica ^c   Laliberté, Franҫois ^b   Germain, Guillaume ^b   Bookhart, Brahim K ^c   Lefebvre, Patrick ^b   Nutescu, Edith A ^d  

^a Univ of Texas College of Pharmacy   (United States)

^b GROUPE D ANALYSE   (Canada)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Costs and cost analysis; Hospital costs; Hospitalization; Pulmonary embolism; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG COST; FEMALE; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE UNIT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COHORT ANALYSIS; COST; ECONOMICS; HOSPITALIZATION; MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84921540574     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.024     Document Type: Article

References (23)

1. Heit JA, Cohen AT, Anderson FA. Estimated Annual Number of Incident and Recurrent, Non- Fatal and Fatal VenousThromboembolism (VTE) Events in the US. Blood 2005;106:267A.
2. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011;86(2):217-20.
3. Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012;108(2):291-302.
4. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011;14(1):65-74.
5. Lefebvre P, Laliberté F, Nutescu E a, Duh MS, LaMori J, Bookhart BK, et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012;18(5):363-74.
6. Kearon C, Akl E a, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
7. Fonseca E, Walker DR, Hill J, Hess GP. Abstract 282: Dabigatran Etexilate is Associated with Shorter Hospital Length of Stay Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:A282.
8. Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30(4):645-53.
9. Van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014:24432872.
10. Cowper PA, Pan W, Anstrom K, Stafford J, Lopes R, Davidson-Ray L, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of Apixaban therapy on resource use in the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. J Am Coll Cardiol 2013;61(10):E1576.
11. Cohen J. Statistical power analysis for the behavioral sciences. Toronto Academic Press, Inc; 1977 19-24.
12. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54(4):387-98.
13. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat Simul Comput 2009;38(6):1228-34.
14. Centers for Disease Control and Prevention (CDC).. Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2012;61(22):401-4.
15. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13(6):475-86.
16. The Joint Commission. National Patient Safety Goals Effective January 1, 2014; 2013 1-7.
17. Biscup-Horn PJ, Streiff MB, Ulbrich TR, Nesbit TW, Shermock KM. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother 2008;42(6):777-82.
18. Clayville LR, Anderson KV, Miller S a, St Onge EL. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T PeerRev J Formul Manag 2011;36(2):86-99.
19. Clayville LR, Anderson KV, Miller S a, St Onge EL. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T PeerRev J Formul Manag 2011;36(2):86-99.
20. Dobesh PP. Economic implications of inadequate treatment of venous thromboembolism and potential solutions. J Pharm Pract 2014;27(2):178-86.
21. Smoyer-Tomic K, Siu K, Walker DR, Johnson BH, Smith DM, Sander S, et al. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs 2012;12(6):403-13.
22. Van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AWa. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30(5):829-37.
23. Cohen A, Chiu KM, Park K, Jeyaindran S, Tambunan KL, Ward C, et al. Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulants. Thromb Res 2012;130(3):291-301.